Blincyto TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: inert substance, blinatumomab
Pack: Blincyto (1 x Blincyto vial, 1 x Blincyto IV Stabiliser vial), 1 pack
Brand name
(ARTG)
: BLINCYTO blinatumomab (rch) 38.5 microgram powder for injection vial with Intravenous (IV) solution stabiliserDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
Blincyto is indicated for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).,Blincyto is indicated for the treatment of minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukaemia (ALL) in patients in complete haematological remission.,Note to indication: the indications in Philadelphia positive, MRD positive and paediatric patients were approved based on phase II, non-randomised evidence. An improvement in clinical outcomes by direct prospective comparison in a randomised setting relative to other standard-of-care salvage therapies has not been established.
How to use this medicine
(ARTG)
This medicine is a pack that contains more than one component.
Component :
- Injection, powder for
- Intravenous
- White to off-white lyophillised powder
Component :
- Injection, solution
- Intravenous
- Colourless to slightly yellow and clear to slightly opalescent solution
Storage conditions
(ARTG)
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Protect from direct sunlight
- Store in Original Container
- Shelf lifetime is 60 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 1 vial Blincyto and 1 vial IV solution stabiliser for Blincyto supplied in composite pack pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on September, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient blinatumomab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
